Allarity Therapeutics Statistics
Total Valuation
ALLR has a market cap or net worth of $3.92 million. The enterprise value is -$14.27 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ALLR has 4.43 million shares outstanding.
| Current Share Class | 4.43M |
| Shares Outstanding | 4.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +215.59% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 2.56% |
| Float | 4.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.06 |
| Quick Ratio | 2.00 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.86 |
Financial Efficiency
Return on equity (ROE) is -541.17% and return on invested capital (ROIC) is -187.21%.
| Return on Equity (ROE) | -541.17% |
| Return on Assets (ROA) | -63.52% |
| Return on Invested Capital (ROIC) | -187.21% |
| Return on Capital Employed (ROCE) | -148.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.19M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -381,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.44% in the last 52 weeks. The beta is -0.07, so ALLR's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | -99.44% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 2.75 |
| Relative Strength Index (RSI) | 42.95 |
| Average Volume (20 Days) | 2,452,999 |
Short Selling Information
The latest short interest is 478,562, so 10.79% of the outstanding shares have been sold short.
| Short Interest | 478,562 |
| Short Previous Month | 656,477 |
| Short % of Shares Out | 10.79% |
| Short % of Float | 10.79% |
| Short Ratio (days to cover) | 0.30 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -17.54M |
| Pretax Income | n/a |
| Net Income | -25.15M |
| EBITDA | -17.53M |
| EBIT | -17.54M |
| Earnings Per Share (EPS) | -$15.65 |
Full Income StatementBalance Sheet
The company has $19.53 million in cash and $1.35 million in debt, giving a net cash position of $18.18 million or $4.10 per share.
| Cash & Cash Equivalents | 19.53M |
| Total Debt | 1.35M |
| Net Cash | 18.18M |
| Net Cash Per Share | $4.10 |
| Equity (Book Value) | 11.81M |
| Book Value Per Share | 1.62 |
| Working Capital | 11.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.35 million and capital expenditures -$298,000, giving a free cash flow of -$15.82 million.
| Operating Cash Flow | -17.35M |
| Capital Expenditures | -298,000 |
| Free Cash Flow | -15.82M |
| FCF Per Share | -$3.57 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |